DISEASE CHARACTERISTICS:

• Biopsy-confirmed lymphoma, meeting 1 of the following criteria:

  • Hodgkin lymphoma of any subtype except nodular L&H lymphocyte predominant

    • Partial response after standard chemotherapy
    • First relapse after initial complete remission with standard chemotherapy

  • Intermediate-grade or high-grade non-Hodgkin lymphoma* (working formulation groups D-H and J)

    • First complete remission after standard chemotherapy with high-risk features as specified by the International Prognostic Index
    • Partial response after standard chemotherapy
    • Relapse after initial complete remission with standard chemotherapy NOTE: *A new classification scheme for adult non-Hodgkin lymphoma has been adopted by PDQ. The terminology of "indolent" or "aggressive" lymphoma will replace the former terminology of "low", "intermediate", or "high" grade lymphoma. However, this protocol uses the former terminology.
• HIV seropositive at or before the time of lymphoma diagnosis

• Must be on a multi-drug regimen (excluding azidothymidine [AZT])* to maintain HIV viral load < 50,000 genome copies (gc)/mL

  • If the CD4 count at enrollment is < 100/mm^3, then the viral load should be < 10,000 gc/mL by RT-PCR
  • If the CD4 count is > 100/mm^3 prior to the start of any lymphoma chemotherapy and is > 100/mm^3 for at least 3 months, then the viral load must be < 150,000 gc/mL and clinically stable
  • If no pre-chemotherapy CD4 counts are available, then the viral load alone will be used from enrollment NOTE: *No AZT pre-transplant during stem cell collection and during the immediate period of engraftment post-transplant. Resumption of AZT should not begin until there is evidence of stable engraftment. Therefore, AZT should not be resumed until at least 2 months after last blood product support is used.
• Must be on a prophylactic regimen for pneumocystis pneumonia if the CD4 counts are < 200/mm^3
• Patients with prior marrow involvement must demonstrate < 10% involvement by morphology pre-stem cell collection

• Patients who are not in complete remission must have measurable disease defined as the following:

  • Bidimensionally measurable lesion by medical photograph, CAT scan or MRI scan, or palpation of lesions with both diameters > 2 cm

• Patients with a history of positive CSF cytology that has become negative with intrathecal chemotherapy are eligible

  • Patients should have a negative spinal fluid cytology within 30 days prior to enrollment
• No abnormal cytogenetics on screening bone marrow biopsy

PATIENT CHARACTERISTICS:

Inclusion criteria:

• Karnofsky performance status 70-100%
• SGOT and SGPT < 1.5 x upper limit of normal (ULN)
• Bilirubin < 1.5 x ULN
• Serum creatinine < 2 x ULN and 24-hour urine creatinine clearance > 60 mL/min
• PT/PTT < 2 x normal
• Not pregnant or nursing
• Negative pregnancy test
• FEV_1 OR DLCO > 50% predicted

• LVEF > 50% by 2-D echocardiogram or MUGA scan

  • No cardiomyopathy, congestive heart failure, or dysrhythmia

• Patients who are hepatitis C antibody positive or hepatitis B surface antigen positive without clinical evidence of cirrhosis will be eligible after further evaluation of viral loads

  • Patients with hepatitis B and ongoing evidence of viral replication may require therapy prior to receiving high-dose chemotherapy at the discretion of the treating physician

Exclusion criteria:

• Active bacterial or fungal infection
• AIDS-related opportunistic infection within the past year, excluding treatment-responsive Mycobacterium Avium Intracellular infection, treatment-responsive oral thrush, herpes simplex, or herpes zoster

• Active CMV retinitis or other CMV-related organ dysfunction

  • Patients with a history of treated CMV infection are allowed
• Relapse of pneumocystis carinii pneumonia within the past year
• AIDS-related syndromes or symptoms that pose a perceived excessive risk for transplantation-related morbidity as determined by the principle investigator
• Intractable and severe diarrhea defined as > 1,500 cc of diarrheal fluid/day or diarrhea causing persistent severe electrolyte abnormalities or hypoalbuminemia
• History of grade III hemorrhagic cystitis due to prior chemotherapy

• Any prior malignancy except treated basal cell carcinoma of the skin

  • Patients with cervical dysplasia may be included at the discretion of the treating physician and the principal investigator
• Psychosocial conditions that hinder compliance

PRIOR CONCURRENT THERAPY:

• See Disease Characteristics